Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $466,000.

  • Pharming Group N.V's Long-Term Investments fell 1.08% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 1.08%. This contributed to the annual value of $466,000 for FY2024, which is 79.61% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Long-Term Investments is $466,000, which was down 79.61% from $2.3 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Long-Term Investments registered a high of $7.2 million during FY2021, and its lowest value of $466,000 during FY2024.
  • In the last 3 years, Pharming Group N.V's Long-Term Investments had a median value of $2.3 million in 2023 and averaged $1.8 million.
  • As far as peak fluctuations go, Pharming Group N.V's Long-Term Investments rose by 15.23% in 2020, and later slumped by 79.61% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Long-Term Investments stood at $7.1 million in 2020, then climbed by 1.17% to $7.2 million in 2021, then plummeted by 65.27% to $2.5 million in 2022, then fell by 8.64% to $2.3 million in 2023, then slumped by 79.61% to $466,000 in 2024.